ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AB-101

Also written as “zabalafin”.

Its studies are mostly in Hepatitis B, Chronic · Lymphoma, Non-Hodgkin · Lupus Nephritis · Hodgkin Disease · Dermatitis, Atopic, led by 5 companies.

Drug pageAB-101: every studyMany companies study it; this page follows only the 6 they lead. All 7 studies, academic ones too, with its approvals and label.
Furthest: phase 2, since Dec 4, 20206 company-led studies, 2 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Artiva Biotherapeuticsits history only21 open or runningphase 2since Dec 4, 2020Dec 4, 2020Aug 2027phase 1 · NCT06265220
Affimed10 open or runningphase 2since May 19, 2023May 19, 2023none ahead
Alphyn Biologicsits history only11 open or runningphase 2since Feb 27, 2025Feb 27, 2025none ahead
Applied Biologyits history only10 open or runningearly phase 1since Jul 8, 2018Jul 8, 2018none ahead
Arbutus Biopharmaits history only10 open or runningphase 1since Jul 14, 2023Jul 14, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Affimed only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2023First study: phase 2 study in RecurrenceFirst studyNCT05883449 · 25 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Affimed leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05883449Recurrence · United States2TerminatedNov 7, 202425

How it is read

Names in the registry

  • “AB-101”, 5 entries
  • “zabalafin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.